Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

5-alpha reductase inhibitor

Therapeutic area intelligence for 5-alpha reductase inhibitor with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Companies: 3

Companies

Aurobindo Pharma →

Assets

Finasteride →

Recent signals(6)

RegulatoryAugust 1, 2026

FDA Accepts Supplement for Finasteride by Sun Pharma

The FDA has accepted a supplemental application for Finasteride (ANDA090508) submitted by Sun Pharma.

RegulatoryJuly 11, 2026

FDA Accepts Supplement Application for Finasteride by Sun Pharma

The FDA has accepted a supplemental application for Finasteride submitted by Sun Pharma.

StrategyJuly 9, 2026

FDA Grants Abbreviated Approval for Finasteride ANDA090121

The FDA has granted abbreviated approval for Finasteride under application ANDA090121 submitted by Accord Healthcare.

StrategyJuly 9, 2026

Teva's Finasteride ANDA076511 Receives Abbreviated Approval from FDA

Teva's ANDA076511 for Finasteride has received an Abbreviated Approval from the FDA.

RegulatoryJuly 9, 2026

FDA Grants AP Status for Finasteride ANDA076437 by Dr. Reddy's Labs

The FDA has granted approval status (AP) for Dr. Reddy's Labs' ANDA076437 for Finasteride.

StrategyJuly 9, 2026

Aurobindo Pharma's Finasteride ANDA078341 Receives AP Status

Aurobindo Pharma's ANDA078341 for Finasteride has received an Abbreviated Approval (AP) status from the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.